Abstract
Alzheimer’s disease is characterized by amyloid-β plaques and neurofibrillary tangles composed of tau aggregates. Several β-sheet dyes are already in clinical use to detect amyloid-β plaques by in vivo positron emission tomography (PET), and related dye compounds are being developed for targeting pathological tau aggregates. In contrast to β-sheet binders, antibody-derived ligands should provide greater specificity for detecting tau lesions, and can be tailored to detect various pathological tau epitopes.
For preclinical in vivo evaluation of these ligands prior to PET development, we have established an in vivo imaging system (IVIS) protocol to detect tauopathy in live mice. Antibodies and their derivatives are conjugated with a near infrared fluorescent dye and injected intravenously into anesthetized mice, which subsequently are imaged at various intervals to assess their pathological tau burden, and clearance of the ligand from the brain. The in vivo signal obtained through the skull correlates well with the degree of tau pathology in the mice, and the injected ligand can be found intraneuronally within the brain bound to tau aggregates. Control IgG and injections of the tau antibodies/fragments into wild-type mice or mice with amyloid-β plaques lead to minimal or no signal, confirming the specificity of the approach.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8(6):595–608
Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21(6):394–402
Sigurdsson EM (2018) Immunotherapies for Alzheimer’s disease. In: Rostagno A, Ghiso J (eds) Protein folding disorders in the central nervous system. World Scientific Publishing, Singapore, pp 267–279
Khan A, Corbett A, Ballard C (2017) Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. Expert Rev Neurother 17(7):683–695
Graham WV, Bonito-Oliva A, Sakmar TP (2017) Update on Alzheimer's disease therapy and prevention strategies. Annu Rev Med 68:413–430
Wisniewski T, Drummond E (2016) Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines 15(3):401–415
Khan A, Corbett A, Ballard C (2017) Emerging amyloid and tau targeting treatments for Alzheimer's disease. Expert Rev Neurother 17(7):697–711
Congdon EE, Krishnaswamy S, Sigurdsson EM (2014) Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis 40(Suppl 1):S113–S121
Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE (2017) Small-molecule PET tracers for imaging proteinopathies. Semin Nucl Med 47(5):553–575
Bischof GN, Endepols H, van Eimeren T, Drzezga A (2017) Tau-imaging in neurodegeneration. Methods 130:114–123
Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O'Brien JT (2017) In vivo tau PET imaging in dementia: pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev 36:50–63
Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A (2017) Tau PET imaging: present and future directions. Mol Neurodegener 12(1):19
Krishnaswamy S, Lin Y, Rajamohamedsait WJ, Rajamohamedsait HB, Krishnamurthy P, Sigurdsson EM (2014) Antibody-derived in vivo imaging of tau pathology. J Neurosci 34(50):16835–16850
Congdon EE, Lin Y, Rajamohamedsait HB, Shamir DB, Krishnaswamy S, Rajamohamedsait WJ, Rasool S, Gonzalez V, Levenga J, Gu J, Hoeffer C, Sigurdsson EM (2016) Affinity of tau antibodies for solubilized pathological tau species but not their immunogen or insoluble tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener 11(1):62
Shamir DB, Rosenqvist N, Rasool S, Pedersen JT, Sigurdsson EM (2016) Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach. Alzheimers Dement 12(10):1098–1107
Gu J, Congdon EE, Sigurdsson EM (2013) Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem 288(46):33081–33095
Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86(3):582–590
Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49):16559–16566
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25(4):402–405
Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279(19):20296–20306
Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34):9115–9129
Rajamohamedsait HB, Sigurdsson EM (2012) Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue. In: Sigurdsson EM, Calero M and Gasset M (eds) Springer Protocols, Methods Mol Biol, vol 849, 2nd edn, Springer Humana Press, New York, pp 411–424
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Krishnaswamy, S., Wu, Q., Lin, Y., Rajamohamedsait, W.J., Rajamohamedsait, H.B., Sigurdsson, E.M. (2018). In Vivo Imaging of Tauopathy in Mice. In: Sigurdsson, E., Calero, M., Gasset, M. (eds) Amyloid Proteins. Methods in Molecular Biology, vol 1779. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7816-8_32
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7816-8_32
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7815-1
Online ISBN: 978-1-4939-7816-8
eBook Packages: Springer Protocols